Earnings Data
Report Date
Aug 11, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.09Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented multiple strong positives: robust early efficacy signals (notably cohort 4 AD results), durable responses without rebound, a clean safety profile across >150 patients, supportive biomarker data, favorable PTCL survival metrics versus historical controls, clear plans to expand into multiple indications, and a substantial $189M financing that increases pro forma cash to ~$246M providing runway into Q2 2028. Offsetting factors include materially higher R&D spending, continued quarterly net losses, reliance on small early cohorts pending larger confirmatory trials, timeline uncertainty for registrational data (primary Phase II AD mid-2027; PTCL full readout late 2027), and execution/regulatory risks inherent to multiple concurrent development programs. Overall, the positives (clinical signal, durability, safety, biomarker rationale, and strengthened balance sheet) outweigh the near-term financial and execution challenges, but success depends on upcoming larger trials and interim readouts.Company Guidance
Strong Cohort 4 Efficacy in Atopic Dermatitis
Cohort 4 (n=12) showed a mean percent reduction in EASI of 72% versus 40% for placebo (p=0.035). 75% (9/12) achieved EASI-75 (one additional patient EASI‑74), 25% achieved EASI-90, 33% achieved IGA 0/1, and 92% (11/12) achieved EASI-50. Placebo EASI-75 was ~20% (17% if adjusted for missed visit patients).
Durable Responses with No Rebound
Responses were maintained out to 90 days post-treatment (observed in cohorts 3 and 4) with over 90% of patients not relapsing in the follow-up period, suggesting durable remission and a potential for intermittent dosing strategies.
Favorable Safety Profile and Viral Risk Data
No new safety signals in cohort 4 or across the Phase I program: no hepatic abnormalities, similar minor infection rates versus placebo, and no evidence of EBV reactivation in >150 patients representing >14,000 patient-days of exposure, including long-term treatment (>2 years in some patients).
Biomarker Support for Mechanism of Action
Biomarkers show decreases in IL-4, IL-5 and IL-17, a small reduction in TARC, reduced Th2 cells and an increase in regulatory T cells (Tregs), supporting ITK inhibition-mediated immune rebalancing and providing translational rationale for multiple inflammatory indications.
Progressing Clinical Development Across Multiple Indications
Initiated a randomized Phase II atopic dermatitis trial (200 patients, 4 arms; doses: 200 mg QD, 200 mg BID, 400 mg QD, placebo; 12-week treatment + 90-day follow-up) with data anticipated mid-2027; ongoing Phase III PTCL enrollment with an interim analysis later this year; planned Phase II trials for hidradenitis suppurativa (~60 patients) and asthma (~150 patients) later this year; Angel Pharmaceuticals conducting a blinded Phase Ib/II AD trial in China with initial cohort results expected late this year.
Positive Phase I/Ib PTCL Signal vs Historical Controls
Phase I/Ib PTCL results (200 mg BID cohort) showed median progression-free survival (PFS) of 6.2 months and median overall survival (OS) of 28 months, comparing favorably to historical chemotherapy PFS <3.5 months and median OS <12 months.
Strengthened Financial Position via Upsized Financing
Closed an upsized underwritten public offering in January that generated net proceeds of $189 million; cash, cash equivalents and marketable securities were $56.8 million at Dec 31, 2025 (vs $52.0M at Dec 31, 2024, ≈+9.2%), and pro forma cash including the financing was ~ $246 million, extending the cash runway into Q2 2028 and beyond key planned data readouts.
DE:C17 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:C17 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | €12.79 | €12.28 | -3.99% |
Mar 12, 2026 | €13.88 | €13.56 | -2.31% |
Nov 04, 2025 | €6.40 | €6.62 | +3.44% |
Aug 07, 2025 | €3.44 | €3.42 | -0.73% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Corvus Pharmaceuticals Inc. (DE:C17) report earnings?
Corvus Pharmaceuticals Inc. (DE:C17) is schdueled to report earning on Aug 11, 2026, TBA (Confirmed).
What is Corvus Pharmaceuticals Inc. (DE:C17) earnings time?
Corvus Pharmaceuticals Inc. (DE:C17) earnings time is at Aug 11, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Corvus Pharmaceuticals Inc. stock?
The P/E ratio of Corvus Pharmaceuticals is N/A.
What is DE:C17 EPS forecast?
DE:C17 EPS forecast for the fiscal quarter 2026 (Q2) is -0.14.